(THC) Tenet Healthcare - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US88033G4073
Stock: Hospitals, Clinics, Surgery Centers, Emergency Care, Imaging
Total Rating 68
Risk 83
Buy Signal 0.19
| Risk 5d forecast | |
|---|---|
| Volatility | 37.6% |
| Relative Tail Risk | -6.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.60 |
| Alpha | 70.54 |
| Character TTM | |
|---|---|
| Beta | 1.064 |
| Beta Downside | 1.091 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.90% |
| CAGR/Max DD | 1.72 |
EPS (Earnings per Share)
Revenue
Description: THC Tenet Healthcare March 05, 2026
Tenet Healthcare Corporation (THC) is a diversified healthcare services company operating in the United States. It encompasses two primary segments: Hospital Operations and Services, and Ambulatory Care.
The Hospital Operations segment provides a comprehensive range of acute care services, including surgical, intensive care, and specialized medical treatments. This segment is typical for large hospital systems, offering a wide array of inpatient and outpatient services.
The Ambulatory Care segment focuses on outpatient procedures and services, such as those offered in ambulatory surgery centers and urgent care facilities. This business model reflects a broader industry trend towards shifting certain procedures from inpatient to outpatient settings for cost efficiency and patient convenience.
To further understand THCs market position and financial health, consider exploring its detailed financial metrics on ValueRay.
Headlines to watch out for
- Hospital admissions and patient volumes impact revenue
- Government healthcare policy changes affect reimbursement rates
- Labor costs for nurses and staff influence profitability
- Acquisition and divestiture of facilities alters market share
- Interest rate fluctuations impact debt servicing costs
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 1.41b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 4.67 > 1.0 |
| NWC/Revenue: 15.89% < 20% (prev 16.32%; Δ -0.43% < -1%) |
| CFO/TA 0.12 > 3% & CFO 3.54b > Net Income 1.41b |
| Net Debt (10.29b) to EBITDA (4.47b): 2.30 < 3 |
| Current Ratio: 1.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.9m) vs 12m ago -8.31% < -2% |
| Gross Margin: 55.91% > 18% (prev 0.40%; Δ 5551 % > 0.5%) |
| Asset Turnover: 72.71% > 50% (prev 71.42%; Δ 1.30% > 0%) |
| Interest Coverage Ratio: 5.16 > 6 (EBITDA TTM 4.47b / Interest Expense TTM 699.0m) |
Altman Z'' 2.27
| A: 0.11 (Total Current Assets 7.85b - Total Current Liabilities 4.46b) / Total Assets 29.68b |
| B: 0.15 (Retained Earnings 4.42b / Total Assets 29.68b) |
| C: 0.12 (EBIT TTM 3.60b / Avg Total Assets 29.31b) |
| D: 0.20 (Book Value of Equity 4.24b / Total Liabilities 20.70b) |
| Altman-Z'' Score: 2.27 = BBB |
Beneish M -3.45
| DSRI: 0.81 (Receivables 2.56b/3.05b, Revenue 21.31b/20.66b) |
| GMI: 0.71 (GM 55.91% / 39.72%) |
| AQI: 1.07 (AQ_t 0.52 / AQ_t-1 0.49) |
| SGI: 1.03 (Revenue 21.31b / 20.66b) |
| TATA: -0.07 (NI 1.41b - CFO 3.54b) / TA 29.68b) |
| Beneish M-Score: -3.45 (Cap -4..+1) = AA |
What is the price of THC shares?
As of March 09, 2026, the stock is trading at USD 236.95 with a total of 811,734 shares traded.
Over the past week, the price has changed by +0.78%, over one month by +22.80%, over three months by +14.85% and over the past year by +87.83%.
Over the past week, the price has changed by +0.78%, over one month by +22.80%, over three months by +14.85% and over the past year by +87.83%.
Is THC a buy, sell or hold?
Tenet Healthcare has received a consensus analysts rating of 4.32.
Therefore, it is recommended to buy THC.
- StrongBuy: 12
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the THC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 257 | 8.5% |
| Analysts Target Price | 257 | 8.5% |
THC Fundamental Data Overview March 05, 2026
P/E Trailing = 15.6798
P/E Forward = 14.0647
P/S = 1.0017
P/B = 4.8452
P/EG = 5.6249
Revenue TTM = 21.31b USD
EBIT TTM = 3.60b USD
EBITDA TTM = 4.47b USD
Long Term Debt = 13.09b USD (from longTermDebt, last quarter)
Short Term Debt = 79.0m USD (from shortTermDebt, last quarter)
Debt = 13.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.29b USD (from netDebt column, last quarter)
Enterprise Value = 31.63b USD (21.35b + Debt 13.17b - CCE 2.88b)
Interest Coverage Ratio = 5.16 (Ebit TTM 3.60b / Interest Expense TTM 699.0m)
EV/FCF = 12.50x (Enterprise Value 31.63b / FCF TTM 2.53b)
FCF Yield = 8.00% (FCF TTM 2.53b / Enterprise Value 31.63b)
FCF Margin = 11.87% (FCF TTM 2.53b / Revenue TTM 21.31b)
Net Margin = 6.60% (Net Income TTM 1.41b / Revenue TTM 21.31b)
Gross Margin = 55.91% ((Revenue TTM 21.31b - Cost of Revenue TTM 9.40b) / Revenue TTM)
Gross Margin QoQ = 41.52% (prev 58.33%)
Tobins Q-Ratio = 1.07 (Enterprise Value 31.63b / Total Assets 29.68b)
Interest Expense / Debt = 0.63% (Interest Expense 83.0m / Debt 13.17b)
Taxrate = 5.43% (37.0m / 681.0m)
NOPAT = 3.41b (EBIT 3.60b * (1 - 5.43%))
Current Ratio = 1.76 (Total Current Assets 7.85b / Total Current Liabilities 4.46b)
Debt / Equity = 3.12 (Debt 13.17b / totalStockholderEquity, last quarter 4.22b)
Debt / EBITDA = 2.30 (Net Debt 10.29b / EBITDA 4.47b)
Debt / FCF = 4.07 (Net Debt 10.29b / FCF TTM 2.53b)
Total Stockholder Equity = 4.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.80% (Net Income 1.41b / Total Assets 29.68b)
RoE = 34.82% (Net Income TTM 1.41b / Total Stockholder Equity 4.04b)
RoCE = 21.04% (EBIT 3.60b / Capital Employed (Equity 4.04b + L.T.Debt 13.09b))
RoIC = 19.80% (NOPAT 3.41b / Invested Capital 17.22b)
WACC = 6.31% (E(21.35b)/V(34.52b) * Re(9.84%) + D(13.17b)/V(34.52b) * Rd(0.63%) * (1-Tc(0.05)))
Discount Rate = 9.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -8.13%
[DCF] Terminal Value 86.97% ; FCFF base≈1.96b ; Y1≈2.42b ; Y5≈4.13b
[DCF] Fair Price = 1093 (EV 105.36b - Net Debt 10.29b = Equity 95.07b / Shares 87.0m; r=6.31% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 82.04 | EPS CAGR: 26.79% | SUE: 1.32 | # QB: 1
Revenue Correlation: 82.31 | Revenue CAGR: 4.15% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.22 | Chg7d=+0.012 | Chg30d=+0.190 | Revisions Net=+6 | Analysts=18
EPS current Year (2026-12-31): EPS=16.93 | Chg7d=+0.053 | Chg30d=+0.663 | Revisions Net=+11 | Growth EPS=+0.9% | Growth Revenue=+3.5%
EPS next Year (2027-12-31): EPS=17.51 | Chg7d=-0.015 | Chg30d=-0.403 | Revisions Net=-3 | Growth EPS=+3.4% | Growth Revenue=+2.3%
[Analyst] Revisions Ratio: +0.50 (9 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.5% (Discount Rate 9.8% - Earnings Yield 6.4%)
[Growth] Growth Spread = -0.2% (Analyst 3.3% - Implied 3.5%)
P/E Forward = 14.0647
P/S = 1.0017
P/B = 4.8452
P/EG = 5.6249
Revenue TTM = 21.31b USD
EBIT TTM = 3.60b USD
EBITDA TTM = 4.47b USD
Long Term Debt = 13.09b USD (from longTermDebt, last quarter)
Short Term Debt = 79.0m USD (from shortTermDebt, last quarter)
Debt = 13.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.29b USD (from netDebt column, last quarter)
Enterprise Value = 31.63b USD (21.35b + Debt 13.17b - CCE 2.88b)
Interest Coverage Ratio = 5.16 (Ebit TTM 3.60b / Interest Expense TTM 699.0m)
EV/FCF = 12.50x (Enterprise Value 31.63b / FCF TTM 2.53b)
FCF Yield = 8.00% (FCF TTM 2.53b / Enterprise Value 31.63b)
FCF Margin = 11.87% (FCF TTM 2.53b / Revenue TTM 21.31b)
Net Margin = 6.60% (Net Income TTM 1.41b / Revenue TTM 21.31b)
Gross Margin = 55.91% ((Revenue TTM 21.31b - Cost of Revenue TTM 9.40b) / Revenue TTM)
Gross Margin QoQ = 41.52% (prev 58.33%)
Tobins Q-Ratio = 1.07 (Enterprise Value 31.63b / Total Assets 29.68b)
Interest Expense / Debt = 0.63% (Interest Expense 83.0m / Debt 13.17b)
Taxrate = 5.43% (37.0m / 681.0m)
NOPAT = 3.41b (EBIT 3.60b * (1 - 5.43%))
Current Ratio = 1.76 (Total Current Assets 7.85b / Total Current Liabilities 4.46b)
Debt / Equity = 3.12 (Debt 13.17b / totalStockholderEquity, last quarter 4.22b)
Debt / EBITDA = 2.30 (Net Debt 10.29b / EBITDA 4.47b)
Debt / FCF = 4.07 (Net Debt 10.29b / FCF TTM 2.53b)
Total Stockholder Equity = 4.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.80% (Net Income 1.41b / Total Assets 29.68b)
RoE = 34.82% (Net Income TTM 1.41b / Total Stockholder Equity 4.04b)
RoCE = 21.04% (EBIT 3.60b / Capital Employed (Equity 4.04b + L.T.Debt 13.09b))
RoIC = 19.80% (NOPAT 3.41b / Invested Capital 17.22b)
WACC = 6.31% (E(21.35b)/V(34.52b) * Re(9.84%) + D(13.17b)/V(34.52b) * Rd(0.63%) * (1-Tc(0.05)))
Discount Rate = 9.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -8.13%
[DCF] Terminal Value 86.97% ; FCFF base≈1.96b ; Y1≈2.42b ; Y5≈4.13b
[DCF] Fair Price = 1093 (EV 105.36b - Net Debt 10.29b = Equity 95.07b / Shares 87.0m; r=6.31% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 82.04 | EPS CAGR: 26.79% | SUE: 1.32 | # QB: 1
Revenue Correlation: 82.31 | Revenue CAGR: 4.15% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.22 | Chg7d=+0.012 | Chg30d=+0.190 | Revisions Net=+6 | Analysts=18
EPS current Year (2026-12-31): EPS=16.93 | Chg7d=+0.053 | Chg30d=+0.663 | Revisions Net=+11 | Growth EPS=+0.9% | Growth Revenue=+3.5%
EPS next Year (2027-12-31): EPS=17.51 | Chg7d=-0.015 | Chg30d=-0.403 | Revisions Net=-3 | Growth EPS=+3.4% | Growth Revenue=+2.3%
[Analyst] Revisions Ratio: +0.50 (9 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.5% (Discount Rate 9.8% - Earnings Yield 6.4%)
[Growth] Growth Spread = -0.2% (Analyst 3.3% - Implied 3.5%)